Shenzhou Cell Engineering's 'Bevacizumab' Applied for Listing
On April 22, China Cell Engineering's "bevacizumab" biosimilar drug was declared for listing.
Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and blocks its biological activity, reducing tumor angiogenesis, thereby inhibiting tumor growth. This is a veritable blockbuster drug. The original research came from Roche, and its peak sales exceeded 7 billion US dollars. However, in recent years, sales have declined due to the impact of similar drugs.
Bevacizumab is the most competitive biosimilar drug in China, and 9 products, including the original drug, have been approved for marketing, from Innovent Bio, Fuhong Henlius, Qilu Pharmaceutical, Hengrui Medicine, Boan Biology, TOT BIOPHARM, Bio-Otai. Before the listing of Shenzhou Cell Engineering News today, Chia Tai Tianqing has also submitted a listing application, and 9 more models are in Phase III clinical trials.
You May Interested In
2026-08-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Wanhua USA Reaches $7.75 Million Settlement in MDI/TDI Antitrust Lawsuit
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
Chemical Tanker Explodes Off Oman Coast, Maritime Security Risk Escalates Again
-
Kemira Acquires AquaBlue
-
“Zero Tariff Is Not a Get-Out-of-Jail-Free Card”: Hainan’s Full Customs Closure—Boon or Trap for the Chemical Industry?
-
“Soaring Sulfuric Acid, Tightening Ore Supplies”: The High-Stakes Battle Behind the Titanium Dioxide Price Surge
-
“Did They Just Buy a Money Printer for ¥288 Million?”: Yip’s Chemical’s Bold Bet on Green Tech—Is This a Genuine Transformation or Just Another Story for the Stock Market?
-
Agrochemical Markets at a Crossroads: Winter Stockpiling Begins Amid Cost Pressures and Fragmented Demand
-
Jiangsu Fengshan Biochem Gears Up for Strategic Expansion in Selective Herbicide Intermediates and Active Ingredients
Recommend Reading
-
Afidopyropen: The Silent Assassin of Sap-Sucking Pests—Promise, Pitfalls, and the Path to Sustainable Deployment
-
Arkema's New Singapore Plant Commences Operations, Tripling Polyamide Capacity
-
Continental Tires Out, Franchise Power In: Continental Group Spins Off French Retail Arm to ASC in Strategic Pivot
-
Global Chemical Inventories Hit Critical Lows as Over 200 Chinese Companies Suspend Quotations
-
Rising Naphtha Prices in Japan Drive Up Costs for Diapers, Sanitary Products, and Cosmetics
-
Business Society Petroleum Coke Daily Review: Overall Downward Trend on August 7, 2026
-
July MTBE market price increase in China is significant
-
FDA Lifts Administrative Stay, Restoring Red No. 3 Ban Timeline for Food and Ingested Drugs
-
This Week's Pure Benzene Market Prices Declined in China (8.3-8.7)
-
Business Society MIBK Daily Review: Overall Stability on August 7, 2026